Treatment with a once-daily FGFR1-3 tyrosine kinase inhibitor led to significant increases in growth among children with achondroplasia, the phase III PROPEL 3 study showed. The l ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results